Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 History  




2 References  













Eprosartan






●العربية
 ●تۆرکجه
 ●Cymraeg
 ●Deutsch
 ●فارسی
 ●Français
 ●Italiano
 ●Magyar
 ●日本語
 ●Polski
 ●Português
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Suomi
 ●Türkçe
 ●Українська
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Eprosartan
Clinical data
Trade namesTeveten
AHFS/Drugs.comMonograph
MedlinePlusa601237
License data
Pregnancy
category
  • AU:D
    • Routes of
    administration    		By mouth
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
  • US: ℞-only
    • Pharmacokinetic data
    Bioavailability15% (Eprosartan mesylate)
    Metabolismnot metabolized
    Elimination half-life5 to 9 hours
    ExcretionKidney 10%, bile duct 90%
    Identifiers

    • 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
  • as mesylate: D02082 checkY
    • ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC23H24N2O4S
    Molar mass424.52 g·mol−1
    3D model (JSmol)

    • O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3

    • InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ checkY

    • Key:OROAFUQRIXKEMV-LDADJPATSA-N checkY

      (verify)

    Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]

    Eprosartan is sometimes paired with hydrochlorothiazide.[2]

    As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (anACE inhibitor), especially among the elderly.[3]

    History[edit]

    The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]

    References[edit]

    1. ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
  • ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
  • ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
  • ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Eprosartan&oldid=1190943533"
    Categories: 
    ●Angiotensin II receptor antagonists
     ●Imidazoles
     ●Thiophenes
     ●Drugs developed by AbbVie
     ●Benzoic acids
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Multiple chemicals in Infobox drug
     ●Chemicals using indexlabels
     ●Drugboxes which contain changes to watched fields
      


    ●This page was last edited on 20 December 2023, at 19:27 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki